2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.034

Change

-0.07 (-1.08)%

Market Cap

USD 0.52B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+1.17 (+2.33%)

USD 484.40B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.38 (+2.35%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.62 (+2.37%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.63 (+2.30%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.66 (+2.76%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+3.78 (+2.75%)

USD 98.29B
JARI:XETRA Amundi Index Solutions - Amund..

+0.79 (+1.74%)

USD 98.25B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+1.15 (+2.31%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+6.54 (+1.22%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.43 (+1.90%)

USD 79.79B

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.72% 49% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.72% 48% F 50% F
Trailing 12 Months  
Capital Gain 8.47% 50% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.47% 50% F 52% F
Trailing 5 Years  
Capital Gain 40.42% 60% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.42% 58% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.92% 56% F 55% F
Dividend Return 5.92% 55% F 53% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.07% 44% F 55% F
Risk Adjusted Return 42.08% 50% F 54% F
Market Capitalization 0.52B 68% D+ 60% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.